Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Pregnant Women at High Risk Following C.S.

Trial Profile

Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Pregnant Women at High Risk Following C.S.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbetocin (Primary) ; Misoprostol (Primary)
  • Indications Postpartum haemorrhage
  • Focus Therapeutic Use

Most Recent Events

  • 30 Jan 2021 Planned End Date changed from 1 Aug 2019 to 1 Aug 2021.
  • 30 Jan 2021 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.
  • 21 Nov 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top